Development of donepezil-induced hypokalemia following treatment of cognitive impairment
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Donepezil is a cholinesterase inhibitor used extensively to treat Alzheimer disease. The increased cholinergic activity is associated with adverse effects, therefore gastrointestinal symptoms, including nausea, vomiting, and diarrhea, are common. Hypokalemia is a rare adverse event that occurs in less than 1% of donepezil-treated patients. Although hypokalemia of mild and moderate grade does not present serious signs and symptoms, severe hypokalemia often results in prolonged hospitalization and mortality. Herein, we report a case of hypokalemia developed after the initiation of donepezil therapy for cognitive impairment.
Abstract
Donepezil is a cholinesterase inhibitor used extensively to treat Alzheimer disease. The increased cholinergic activity is associated with adverse effects, therefore gastrointestinal symptoms, including nausea, vomiting, and diarrhea, are common. Hypokalemia is a rare adverse event that occurs in less than 1% of donepezil-treated patients. Although hypokalemia of mild and moderate grade does not present serious signs and symptoms, severe hypokalemia often results in prolonged hospitalization and mortality. Herein, we report a case of hypokalemia developed after the initiation of donepezil therapy for cognitive impairment.
참고문헌 (16)
- Crop MJ, "Hypokalaemia and subsequent hyperkalaemia in hospitalized patients", Nephrol Dial Transplant, 22, pp.3471~3477 (2007)
- Widodo D, "The prevalence of hypokalemia in hospitalized patients with infectious diseases problem at Cipto Mangunkusumo Hospital, Jakarta", Acta Med Indones, 38, pp.202~205 (2006)
- Unwin RJ, "Pathophysiology and management of hypokalemia : a clinical perspective", Nat Rev Nephrol, 7, pp.75~84 (2011)
- Paltiel O, "Management of severe hypokalemia in hospitalized patients : a study of quality of care based on computerized databases", Arch Intern Med, 161, pp.1089~1095 (2001)
- Li HC, "Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: a case report", Medicine(Baltimore), 99, pp.e19443~ (2020)
- Arai H, "Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer’s disease : Japan-Great Outcome of Long-term trial with Donepezil(J-GOLD)", Psychogeriatrics, 18, pp.402~411 (2018)
- Cubeddu LX, "Drug-induced inhibition and trafficking disruption of ion channels : pathogenesis of QT abnormalities and drug-induced fatal arrhythmias", Curr Cardiol Rev, 12, pp.141~154 (2016)
- Manzo C, "Drug-induced lupus erythematosus associated with donepezil : a case report", Age Ageing, 44, pp.1062~1063 (2015)
- "Highlights of prescribing information: Aricept" (2012)[URL]
- "Will you have hypokalemia with Donepezil?" (2020)[URL]
- Li XL, "Behavioral and psychological symptoms in Alzheimer’s disease", Biomed Res Int, 2014, pp.927804~ (2014)
- Seltzer B, "Donepezil : a review", Expert Opin Drug Metab Toxicol, 1, pp.527~536 (2005)
- Dunn NR, "Adverse effects associated with the use of donepezil in general practice in England", J Psychopharmacol, 14, pp.406~408 (2000)
- Jackson S, "The safety and tolerability of donepezil in patients with Alzheimer’s disease", Br J Clin Pharmacol, 58(Suppl 1), pp.1~8 (2004)
- Tabish M, "Colistin-induced acquired Bartter-like syndrome : an unusual cause of meltdown", BMJ Case Rep, 13, pp.e232630~ (2020)
- Min HK, "Rifampin-associated tubulointersititial nephritis and Fanconi syndrome presenting as hypokalemic paralysis", BMC Nephrol, 14, pp.13~ (2013)